5 news items
Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
GH
3 Jun 24
.
"This landmark study highlights the importance of equitable access to precision medicine," said Craig Eagle, MD
FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
GH
23 May 24
.
2. American Cancer Society. Key Statistics for Colorectal Cancer. Accessed online May 21, 2024
Guardant Health to Participate in Upcoming Investor Conferences
GH
22 May 24
:00 p.m. ET / 11:00 a.m. PT
Interested parties may access live and archived webcasts
Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
GH
21 May 24
liquid biopsy is a significant milestone for cancer care in the EU, as the test provides faster access to comprehensive genomic profiling
Guardant Health to Participate in Upcoming Investor Conferences
GH
7 May 24
at 3:00 p.m. CT / 4:00 p.m. ET
Interested parties may access live and archived webcasts
- Prev
- 1
- Next